Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | MIF | P14174 | 5/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19052803 | 0.84 | BRD4 (0.51) | BRD4GAATSHRMIFHDAC6 | |
| SCHEMBL52516 | 0.84 | BRD4 (0.51) | BRD4GAATSHRMIFHDAC6 | |
| SCHEMBL14235505 | 0.84 | BRD4 (0.51) | BRD4GAATSHRMIFHDAC6 | |
| SCHEMBL11247378 | 0.83 | BRD4 (0.49) | BRD4GAATSHRMIFHDAC6 | |
| SCHEMBL11247387 | 0.83 | BRD4 (0.49) | BRD4GAATSHRMIFHDAC6 | |
| SCHEMBL337398 | 0.81 | BRD4 (0.49) | BRD4GAATSHRMIFHSD17B10 | |
| SCHEMBL31645448 | 0.81 | BRD4 (0.49) | BRD4GAATSHRMIFHSD17B10 | |
| SCHEMBL30045918 | 0.81 | BRD4 (0.49) | BRD4GAATSHRMIFHSD17B10 | |
| SCHEMBL10413120 | 0.80 | BRD4 (0.47) | BRD4TSHRHSD17B10KMT2AL3MBTL1 | |
| SCHEMBL26430857 | 0.79 | BRD4 (0.39) | BRD4GAAMIFKMT2ANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502376-B2 | Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250034110-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. | 2025-01-30 | — | — | US | disclosed |
| US-12116343-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-15 | — | — | US | disclosed |
| EP-4380560-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Contineum Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118043041-A | LPAR1 antagonists and uses thereof | 康蒂内乌姆医疗公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230339915-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| EP-3746444-B1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-09-27 | — | — | EP | disclosed |
| US-8193349-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193349-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| EP-2207775-B1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| EP-2207775-B1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| EP-2207775-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | Novartis Ag (CH) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009059943-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009059943-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12502376-B2 | Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | SERPINA2, SERPINB1, SERPINE1 | BRD4 738/4885GAA 1355/4885TSHR 1925/4885 |
| US-12116343-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, NPC1L1 | BRD4 4273/4885GAA 728/4885TSHR 3789/4885 |
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | BRD4 1941/4885GAA 999/4885TSHR 2109/4885 |
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | BRD4 1418/4885GAA 2/4885TSHR 4759/4885 |
| US-20250034110-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | BRD4 1874/4885GAA 2146/4885TSHR 252/4885 |
| US-20090118287-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | BRD4 354/4885GAA 635/4885TSHR 1637/4885 |
| US-20230339915-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | BRD4 2769/4885GAA 139/4885TSHR 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.